{
    "meta": {
        "totalResults": 2,
        "from": 0
    },
    "results": [
        {
            "aliases": [
                {
                    "type": "Synonym",
                    "name": "letrozole-palbociclib"
                },
                {
                    "type": "Synonym",
                    "name": "palbociclib + letrozole"
                },
                {
                    "type": "Synonym",
                    "name": "letrozole + palbociclib"
                },
                {
                    "type": "Synonym",
                    "name": "letrozole/palbociclib"
                },
                {
                    "type": "Synonym",
                    "name": "Femara/Ibrance"
                }
            ],
            "definition": {
                "html": "A chemotherapy regimen consisting of letrozole and palbociclib that is used as a treatment for estrogen receptor (ER) positive and HER-2/neu-negative metastatic or advanced breast cancer.",
                "text": "A chemotherapy regimen consisting of letrozole and palbociclib that is used as a treatment for estrogen receptor (ER) positive and HER-2/neu-negative metastatic or advanced breast cancer."
            },
            "drugInfoSummaryLink": null,
            "nciConceptId": "C142859",
            "nciConceptName": "Letrozole/Palbociclib Regimen",
            "termId": 791794,
            "name": "letrozole/palbociclib regimen",
            "firstLetter": "l",
            "type": "DrugTerm",
            "termNameType": "PreferredName",
            "prettyUrlName": "letrozole-palbociclib-regimen"
        },
        {
            "aliases": [
                {
                    "type": "CodeName",
                    "name": "PD-0332991"
                },
                {
                    "type": "CASRegistryName",
                    "name": "571190-30-2"
                },
                {
                    "type": "CodeName",
                    "name": "PD-332991"
                },
                {
                    "type": "ChemicalStructureName",
                    "name": "6-acetyl-8-cyclopentyl-5-methyl-2-((5-(piperazin-1-yl)pyridin-2-yl)amino)pyrido[2,3-d]pyrimidin-7(8H)-one"
                },
                {
                    "type": "USBrandName",
                    "name": "Ibrance"
                }
            ],
            "definition": {
                "html": "An orally available cyclin-dependent kinase (CDK) inhibitor with potential antineoplastic activity. Palbociclib selectively inhibits cyclin-dependent kinase 4 (CDK4) and 6 (CDK6), thereby inhibiting retinoblastoma (Rb) protein phosphorylation early in the G1 phase leading to cell cycle arrest. This suppresses DNA replication and decreases tumor cell proliferation. CDK4 and 6 are serine/threonine kinases that are upregulated in many tumor cell types and play a key role in the regulation of cell cycle progression.",
                "text": "An orally available cyclin-dependent kinase (CDK) inhibitor with potential antineoplastic activity. Palbociclib selectively inhibits cyclin-dependent kinase 4 (CDK4) and 6 (CDK6), thereby inhibiting retinoblastoma (Rb) protein phosphorylation early in the G1 phase leading to cell cycle arrest. This suppresses DNA replication and decreases tumor cell proliferation. CDK4 and 6 are serine/threonine kinases that are upregulated in many tumor cell types and play a key role in the regulation of cell cycle progression."
            },
            "drugInfoSummaryLink": {
                "uri": "https://www.cancer.gov/about-cancer/treatment/drugs/palbociclib",
                "text": "Palbociclib"
            },
            "nciConceptId": "C49176",
            "nciConceptName": "Palbociclib",
            "termId": 454586,
            "name": "palbociclib",
            "firstLetter": "p",
            "type": "DrugTerm",
            "termNameType": "PreferredName",
            "prettyUrlName": "palbociclib"
        }
    ],
    "links": null
}